Mitsubishi UFJ Capital (Mitsubishi UFJ Financial Group’s venture capital arm) manages life sciences–dedicated funds with approximately $330M AUM, invests about $0.6–6.6M per company from Seed to Series B in therapeutics/healthcare (area/modality agnostic), and targets opportunities with a Japan angle across Japan, Europe, Asia, and the United States.